Serotonin Norepinephrine Reuptake Inhibitor Is Associated With Lower Mortality Among Patients Presenting With Takotsubo Cardiomyopathy.

Document Type

Article

Publication Date

7-2025

Abstract

BACKGROUND: Serotonin-norepinephrine reuptake inhibitors (SNRIs) inhibit the presynaptic reuptake of serotonin and norepinephrine and are widely used in the treatment of depression and neuropathic pain. We evaluate the impact of SNRIs use on the clinical outcomes of patients presenting with Takotsubo cardiomyopathy (TCM).

METHODS: We analyzed data from the TriNetX research network. Patients aged ≥18 years with a principal diagnosis of TCM were identified from January 1, 2003, to December 31, 2023. After excluding patients on SSRIs, stimulants, 5-fluorouracil, capecitabine, gemcitabine, and trastuzumab, patients with myocarditis, pheochromocytoma, acute myocardial infarction, cocaine-related disorders, and opioid-related disorders, were also excluded. The final study population was divided into 2 cohorts: patients on SNRIs and patients not on SNRIs. Propensity score matching was used to adjust for potential confounders. The primary outcome was all-cause mortality, and the secondary outcome was Takotsubo cardiomyopathy-related complications.

RESULTS: A total of 16 853 patients with a diagnosis of TCM were identified, of which 2482 (14.7%) were on SNRIs. The SNRIs cohort were older (mean age 64.1 versus 63.4 years,

CONCLUSIONS: The use of SNRIs among patients presenting with TCM is associated with lower mortality and lower TCM-related complications.

Publication Title

J Am Heart Assoc

Volume

14

Issue

13

First Page

037951

Last Page

037951

Comments

Epub

Link to Full Text

Share

COinS